Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096473 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
A Phase 3 study of Dementia and Alzheimers Disease, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT00096473: Completed Phase 3 study of Dementia and Alzheimers Disease, sponsored by Eisai.
NCT00096473 is a Phase 3 study of Dementia and Alzheimers Disease that has completed, run by Eisai. The registered enrollment target is 229 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096473, a Phase 3 study of Dementia and Alzheimers Disease, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.
Conditions Studied
Interventions
- DRUG Donepezil hydrochloride
Study Locations (20)
Florida
- - Fort Lauderdale
- - Fort Myers
- - North Miami
- - St. Petersburg
Arizona
- - Phoenix
- - Sun City
- - Tucson
California
- - San Francisco
- - Santa Monica
- - Torrance
New Jersey
- - Long Branch
- - Piscataway
Alabama
- - Northport
Colorado
- - Denver
Georgia
- - Atlanta
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00096473 record still lists
NCT00096473 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 1 intervention - of which Donepezil hydrochloride is the first listed.
NCT00096473 names 20 study sites across 12 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00096473 about?
NCT00096473 is a clinical study titled "Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease". Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further inv...
What is the current status of trial NCT00096473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 229 participants. The study started on 2001-01. Estimated completion is 2005-09.
What conditions does trial NCT00096473 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease.
What interventions are being tested in trial NCT00096473?
The interventions under investigation include: Donepezil hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00096473?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00096473 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00096473's enrollment target sits among peer trials
229 84th of 199 higher than 116 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
ACTIVE NOT RECRUITING · Phase 3
-
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Escitalopram for Agitation in Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Preventing Cognitive Decline With Alternative Therapies
COMPLETED · Phase 3
-
High Intensity Light Therapy in Alzheimer's Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia